Eton Pharmaceuticals Inc. (ETON) Reports Q1 EPS of $0.19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Eton Pharmaceuticals Reports Record Revenue and Earnings
May 13, 2021 4:05 PM EDTFirst quarter 2021 revenue of $11.9 millionFirst quarter 2021 operating earnings of $5.4 million; EPS of $0.19Eton now has three commercial, revenue-generating products
DEER PARK, Ill., May 13, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.
We are proud to report record revenue and the first profitable quarter in Etons history, said Sean Brynjelsen, CEO of Eton Pharmaceuticals. We have... More
